Effect of Transcutaneous Vagus Nerve Stimulation at Auricular Concha for Insomnia: A Randomized Clinical Trial

doi:10.1155/2020/6049891

Paper

Effect of Transcutaneous Vagus Nerve Stimulation at Auricular Concha for Insomnia: A Randomized Clinical Trial

Published Aug 6, 2020 · Yue Jiao, Xiao Guo, Man Luo

Evidence-based Complementary and Alternative Medicine : eCAM

Q2 SJR score

24

Citations

1

Influential Citations

Full textSemantic Scholar

Abstract

Insomnia inflicts mental burden and decreases physical productivity and affects life quality. Transcutaneous vagus nerve stimulation (ta-VNS) may be an effective treatment option for insomnia. This study aims to evaluate the effect and safety of ta-VNS and compare it with transcutaneous nonvagus nerve stimulation (tn-VNS). A multicenter, randomized, clinical trial was conducted at 3 hospitals in China enrolling 72 insomnia participants from May 2016 to June 2017. Participants were randomly assigned (1 : 1) to receive 40 sessions of ta-VNS or tn-VNS treatment. 63 participants completed the trial. ta-VNS treatment significantly decreased the Pittsburgh Sleep Quality Index score, Epworth Sleepiness Scale score, Flinders Fatigue Scale score, Hamilton Depression Scale score, and Hamilton Anxiety Scale score over 4 weeks compared with those of the baseline. Moreover, it also significantly increased the 36-item Short-Form Health Survey Questionnaire scores compared with that of the baseline. However, it did not show significant differences compared with tn-VNS in changes of primary and secondary outcomes. The incidence of adverse events was low. ta-VNS significantly relieved insomnia over 4 weeks. Moreover, it also alleviated fatigue and improved participants' quality of life as well as other concomitant symptoms such as depression and anxiety. This trial is registered at Chinese Clinical Trial Registry (http://www.chictr.org.cn) with the registration number: ChiCTR-TRC-13003519.

RCT

Rigorous Journal

Study Snapshot

Transcutaneous vagus nerve stimulation (ta-VNS) significantly relieves insomnia, improves sleep quality, and reduces fatigue and depression, but shows no significant differences compared to transcutaneous nonvagus nerve stimulation (tn-VNS).

PopulationOlder adults (50-71 years)

Sample size24

MethodsObservational

OutcomesBody Mass Index projections

ResultsSocial networks mitigate obesity in older groups.

Sign up to use Study Snapshot

Consensus is limited without an account. Create an account or sign in to get more searches and use the Study Snapshot.

Create an account

Paper

Effect of Transcutaneous Vagus Nerve Stimulation at Auricular Concha for Insomnia: A Randomized Clinical Trial

Sign up to use Study Snapshot

References

Functional Connectivities in the Brain That Mediate the Association Between Depressive Problems and Sleep Quality

Increased functional connectivity between brain regions, including the lateral orbitofrontal cortex and cingulate cortex, mediates the association between depression and poor sleep quality.

Recent advances in devices for vagus nerve stimulation

Novel vagus nerve stimulation devices show promise for treating epilepsy and depression, with potential applications in stroke rehabilitation, chronic heart failure, and rheumatoid arthritis.

[Transcutaneous vagus nerve stimulation for primary insomnia and affective disorder:a report of 35 cases].

Transcutaneous vagus nerve stimulation (taVNS) at auricular concha effectively relieves primary insomnia symptoms and improves depressive and anxiety symptoms, with potential long-term efficacy and safety.

The relationship between epilepsy, sleep disorders, and attention deficit hyperactivity disorder (ADHD) in children: A review of the literature

Epilepsy, sleep disorders, and ADHD in children share a significant link, affecting sleep, behavior, and cognitive deficits.

Effect of transcutaneous auricular vagus nerve stimulation on major depressive disorder: A nonrandomized controlled pilot study.

Transcutaneous auricular vagus nerve stimulation (taVNS) is a promising, safe, and cost-effective therapeutic method for mild and moderate major depressive disorder.

Citations